Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium quadruple live bacteria powder
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium Quadruple Live Bacteria Powder is a combination live biotherapeutic product consisting of four distinct bacterial strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. Developed by Hangzhou Grand Biologic Pharmaceutical, this probiotic formulation is designed to restore and maintain a healthy balance of the intestinal microbiota. The constituent strains work synergistically to regulate gut function; *Bifidobacterium infantis*, *Lactobacillus acidophilus*, and *Enterococcus faecalis* are normal components of the human intestinal flora that colonize the gut and inhibit pathogenic bacteria, while *Bacillus cereus* consumes oxygen to create an anaerobic environment that promotes the growth and reproduction of anaerobic probiotics. The powder formulation is being evaluated in clinical trials, including a Phase II randomized, double-blind, placebo-controlled study, for the treatment of functional constipation in children.
- Other names
- combined bifidobacterium, lactobacillus, enterococcus and bacillus cereus powder, live双歧杆菌四联活菌散
Beyond the preview
Go deeper on bifidobacterium quadruple live bacteria powder.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium quadruple live bacteria powder.